Name: Latest research reports of Equitas Small Finance Bank Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Equitas Small Finance Bank Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	28 Mar 2025	Equitas Small Finance Bank	BOB Capital Markets Ltd.	60.40	73.00	54.98 (9.86%)	20.86	Buy	pdf post cache	Broker Report [Initiation] Equitas Small Finance Bank: De-risked portfolio growth; available at a discount BOB Capital Markets Ltd. Rising share of diversified and secured portfolio with MFI mix likely to decline further; scaling up granular deposit franchise pdf Copy Link Share on Share on Share on Share on Alert
	24 Mar 2025	Suven Pharma	BOB Capital Markets Ltd.	1077.80	1405.00	1175.50 (-8.31%)	30.36	Buy	pdf post cache	Broker Report [Initiation] A play on the ADC growth segment BOB Capital Markets Ltd. ADC is an evolving second line of treatment in oncology. The company expects market size to grow to US$ 50bn by FY33 from US$ 5bn in FY22 pdf Copy Link Share on Share on Share on Share on Alert
	21 Mar 2025	Software & Services	BOB Capital Markets Ltd.					Not Rated	pdf post cache	Broker Report Accenture (NOT RATED): Significant deceleration on the cards. Unsure if worst is over BOB Capital Markets Ltd. YoY organic growth is expected to decelerate from ~4.5% in 2QFY25 to 0.5% in 4Q. Implies a US$2.6bn annualized organic revenue loss pdf Copy Link Share on Share on Share on Share on Alert
	17 Mar 2025	Aurobindo Pharma	BOB Capital Markets Ltd. Reco Target	1164.40	1451.00	1111.70 (4.74%)	24.61	Buy	pdf post cache	Broker Report Aurobindo Pharma (BUY): Growth triggers intact; valuations attractive BOB Capital Markets Ltd. Eugia unit 3 capacity utilization to increase to 60-65% from 50% in Q3FY25. We expect capacity utilisation to rise above 70% in FY26E pdf Copy Link Share on Share on Share on Share on Alert
	11 Mar 2025	IndusInd Bank	BOB Capital Markets Ltd. Reco Target	818.20	870.00	655.95 (24.74%)	6.33	Hold	pdf post cache	Broker Report IndusInd Bank (HOLD): Net worth impact led by accounting discrepancy; HOLD BOB Capital Markets Ltd. Discrepancy in derivative portfolio account to adversely impact net worth by 2.35%, indicates weak internal controls pdf Copy Link Share on Share on Share on Share on Alert
	11 Mar 2025	Supreme Industries	BOB Capital Markets Ltd. Target	3483.80	5150.00	3333.95 (4.49%)	47.83	Buy	pdf post cache	Broker Report Supreme Industries (BUY): Wavin acquisition to bolster SI's market share and return ratios BOB Capital Markets Ltd. Wavin acquisition will enable SI to gain market share in North and South India pdf Copy Link Share on Share on Share on Share on Alert
	10 Mar 2025	Sun Pharmaceutical	BOB Capital Markets Ltd.	1744.80	2086.00	1611.50 (8.27%)	19.56	Buy	pdf post cache	Broker Report Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio BOB Capital Markets Ltd. SUNP to acquire Checkpoint Therapeutic for US$ 4.10 a share, at ~66% premium to its last closing price. Deal valued at US$ 355mn pdf Copy Link Share on Share on Share on Share on Alert
	01 Mar 2025	UltraTech Cement	BOB Capital Markets Ltd.	11364.00	13137.00	10128.45 (12.20%)	15.60	Buy	pdf post cache	Broker Report Ultratech Cement (BUY): Diversification Play; Sharp focus on Cement Stays, Retain BUY BOB Capital Markets Ltd. UTCEM allocates Rs18bn (~2% of capital allocation) in the building material value chain by investing in wire and cable business pdf Copy Link Share on Share on Share on Share on Alert
	24 Feb 2025	Federal Bank	BOB Capital Markets Ltd. Target	187.38	236.00	181.24 (3.39%)	25.95	Buy	pdf post cache	Broker Report Federal Bank (BUY): Unfolding strategy, implementation remains the key BOB Capital Markets Ltd. FB plans to grow advances 1.5x nominal GDP growth in the next three years pdf Copy Link Share on Share on Share on Share on Alert
	17 Feb 2025	Hindware Home Innovation	BOB Capital Markets Ltd. Target	184.97	250.00	194.90 (-5.09%)	35.16	Buy	pdf post cache	Broker Report Hindware Home Innovation (BUY): Another disappointing quarter on muted demand BOB Capital Markets Ltd. Dismal Q3 on weak performance across segments due to muted demand environment pdf Copy Link Share on Share on Share on Share on Alert
more loading

BOB Capital Markets Ltd. Broker Research reports

Latest broker research reports from BOB Capital Markets Ltd. buy, sell, hold, neutral recommendations along with share price targets forecast and upside.

[Initiation] Equitas Small Finance Bank: De-risked portfolio growth; available at a discount

[Initiation] A play on the ADC growth segment

Accenture (NOT RATED): Significant deceleration on the cards. Unsure if worst is over

Aurobindo Pharma (BUY): Growth triggers intact; valuations attractive

IndusInd Bank (HOLD): Net worth impact led by accounting discrepancy; HOLD

Supreme Industries (BUY): Wavin acquisition to bolster SI's market share and return ratios

Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio

Ultratech Cement (BUY): Diversification Play; Sharp focus on Cement Stays, Retain BUY

Federal Bank (BUY): Unfolding strategy, implementation remains the key

Hindware Home Innovation (BUY): Another disappointing quarter on muted demand

Advisor Screeners